Diagnose and Distinguish Early-Stage Dementia in a Matter of 5 Minutes with Brainalyze
In the ongoing quest to combat dementia, a UK-based biotech company, Brainalyze, is developing a groundbreaking solution. The company is working on a **finger-prick blood test** designed for early and accessible diagnosis of dementia, a condition that currently affects millions worldwide.
As of July 2025, Brainalyze's technology has successfully completed the pre-clinical trial stage. The company aims to revolutionise the diagnostic landscape, making early detection more accessible and less invasive compared to current methods like PET scans, lumbar punctures, and cognitive assessments.
Brainalyze's CEO, Professor Sumeet Mahajan, has ambitious goals. He aspires to build a billion-dollar business and pioneer national dementia screening programs. To achieve this, Brainalyze is seeking MedTech and BioTech specialist investors with experience in rapidly bringing healthtech to market and scaling it globally.
The company has secured a £1.2 million research grant for further clinical validation of their proprietary technology. The method developed by Brainalyze has demonstrated accuracy in 93% of cases for identifying and distinguishing Alzheimer's disease from other diseases that cause dementia. Moreover, Brainalyze's technology can detect pre-manifest and track Huntington's disease.
However, it's important to note that as of mid-2025, there is no public, peer-reviewed evidence or official announcements confirming that Brainalyze’s finger-prick blood test has achieved routine clinical use for dementia diagnosis. The current status appears to be early development and initial clinical validation.
In the competitive field of blood-based biomarkers for dementia, Brainalyze's test is one of many promising solutions. Companies like Quanterix, C2N Diagnostics, Roche, and Eli Lilly are also investing heavily in this area. Independent validation is crucial before any test can be trusted clinically.
As we move forward, key milestones to watch for include peer-reviewed publications detailing test performance in relevant patient populations, registered clinical trials, regulatory filings, and funding announcements. These developments would indicate more advanced stages of Brainalyze's test and bring us closer to a future where early, accessible, and minimally invasive diagnostic tools for dementia become a reality.
In the meantime, while minimally invasive blood tests for dementia are an exciting prospect, independent validation, regulatory approval, and clear clinical utility are essential before any such test can be recommended for widespread use.
For more information, you can visit Brainalyze's website, connect with them, or contact Professor Sumeet Mahajan directly at [email protected].
- Brainalyze's finger-prick blood test, currently in early development and initial clinical validation, is designed to revolutionize dementia diagnosis, offering a less invasive alternative to methods like PET scans, lumbar punctures, and cognitive assessments.
- Aiming to build a billion-dollar business and pioneer national dementia screening programs, Brainalyze is seeking MedTech and BioTech specialist investors with a proven track record in rapidly bringing healthtech to market and scaling it globally.
- The method developed by Brainalyze has demonstrated accuracy in 93% of cases for identifying and distinguishing Alzheimer's disease from other diseases that cause dementia, and it can also detect pre-manifest and track Huntington's disease.
- In the competitive landscape of blood-based biomarkers for dementia, Brainalyze's test is one of many promising solutions, with companies like Quanterix, C2N Diagnostics, Roche, and Eli Lilly also investing heavily in this area.
- For any test to be trusted clinically, independent validation is crucial, and as of mid-2025, there is no public, peer-reviewed evidence confirming that Brainalyze’s finger-prick blood test has achieved routine clinical use for dementia diagnosis.
- Key milestones to watch for include peer-reviewed publications detailing test performance in relevant patient populations, registered clinical trials, regulatory filings, and funding announcements, all of which would indicate more advanced stages of Brainalyze's test and bring us closer to a future with early, accessible, and minimally invasive diagnostic tools for dementia.
